New safety issues plague Hep C antivirals

US health authorities have identified hundreds of cases of acute liver failure in patients taking direct-acting antivirals (DAA) for hepatitis C.

A12-month safety review reveals adverse events, including 524 cases of liver failure associated with the drugs, and another 1,058 reports of severe liver injury.

In a further 761 cases the adverse event was antiviral failure against the targeted virus, according to the